RELMADA THERAPEUTICS, INC. (RLMD) [Rocket]

In millions, except per share items	Jun-30-23	Mar-31-23	Sep-30-22	Jun-30-22	Mar-31-22	Sep-30-21	Jun-30-21	Mar-31-21
	10-Q	10-Q	10-Q	10-Q	10-Q	10-Q	10-Q	10-Q
Revenues						-0.4	-0.2	-0.1
Revenue growth						392.7%
Cost of goods sold						-141.2	-90.3	-37.3
Gross profit						140.8	90.1	37.3
Gross margin						-33156.0%	-51832.7%	-74262.4%
Selling, general and administrative [+]						32.2	29.5	27.8
General and administrative						32.2	29.5	27.8
Research and development						80.3	57.5	45.5
Other operating expenses						140.8	90.1	37.3
EBITDA [+]							-87.0	-73.3
EBITDA growth						152.8%	180.6%	227.4%
EBITDA margin						26483.8%	50043.5%	145945.2%
Depreciation and amortization							0.0	0.0
EBIT [+]						-112.4	-87.0	-73.3
EBIT growth						152.8%	180.5%	227.4%
EBIT margin						26484.3%	50045.2%	145952.1%
Interest income						1.3	1.3	1.4
Interest income						1.3	1.3	1.4
Other income (expense), net						-1.0	-0.8	0.9
Pre-tax income						-112.1	-86.4	-71.0
Income taxes						0.0	0.0	0.0
Tax rate						0.0%	0.0%	0.0%
Net income						-112.1	-86.4	-71.0
Net margin						26411.6%	49733.2%	141428.0%

Basic EPS [+]						($6.72)	($5.30)	($4.47)
Growth						115.3%	116.7%	94.7%
Diluted EPS [+]						($6.72)	($5.30)	($4.47)
Growth						115.3%	116.7%	94.7%

Shares outstanding (basic) [+]						16.7	16.3	15.9
Growth						20.5%	33.0%	58.6%
Shares outstanding (diluted) [+]						16.7	16.3	15.9
Growth						20.5%	33.0%	58.6%

EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges.